Drug intelligence / Profile preview

PROCART

Development stage: Unknown
Lead developer: Jointcare Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

PROCART is a branded nutritional supplement developed by Jointcare Pharmaceuticals Pvt Ltd, specifically formulated to support joint health and manage symptoms of osteoarthritis. It is typically administered as an oral tablet. The supplement contains a combination of active ingredients such as chondroitin sulfate, curcumin, and methylsulfonylmethane (MSM), or alternatively, a blend of glucosamine and essential vitamins (C, D3, and E). These components work synergistically to maintain cartilage health, reduce inflammation, and improve joint mobility. PROCART is intended for use in patients with degenerative joint conditions, athletic injuries, or those recovering from orthopedic surgeries.

Brand names: PROCART

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NF-κB

Beyond the preview

Go deeper on PROCART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROCART.

Explore the full profile